when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GENENTECH · news · pharmadog

← back to GENENTECH

News mentioning GENENTECH

43 stories

2dChutes & Ladders—Legend poaches Novartis vet to boost commercial potentialfiercebiotech

2dRoche, Dualitas team up to find bispecific drugs for immune diseasesbiopharma dive

2dRoche signs $1B deal with Dualitas to pair up on big bispecific screening drivefiercebiotech

3dSionna says good-bye to 46% of staffers, including execbiospace

5d5 drugmakers chasing Merck and Moderna in the cancer vaccine racebiospace

8dmRNA cancer vaccines’ biggest barriers to marketbiopharma dive

9dChutes & Ladders—Longtime Takeda R&D chief to depart next Junefiercebiotech

11dSTAT+: Inhibrx claims first win for long-sought immunotherapy targetstat

18dIs Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?fiercebiotech

18dRoche finds another oncology gem in Asia with $1.5B B cell disease partnershipbiospace

18dArsenalBio sheds most of staff in pivot to in vivo CAR-Tfiercebiotech

22dBioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccineendpoints

22dBioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 testfiercebiotech

22dGenentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBiobiospace

22dRoche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistanceendpoints

22dWhy Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical datafiercebiotech

22dGenentech doubles down on ADC-resistant cancers with $1B DualityBio pactfiercebiotech

23dSTAT+: Former Stanford president releases emails to rebut fraud and cover-up allegations in new bookstat

26dRoche bets up to $2.3B in Hanmi pact for next-gen weight loss drugbiospace

26dRoche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismfiercebiotech

29dGenentech invests $750M in new factory; Bavarian Nordic delays Lyme trialendpoints

29dSTAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and morestat

29dReplimune lands commercial chief after hard-fought approval; Neumora's Paul Berns sheds CEO titleendpoints

Aug 20, 26Roche pours $750M into Oregon manufacturing plant as obesity push expandsbiospace

Aug 20, 26Chutes & Ladders—Neumora shuffles leadership ahead of INDfiercebiotech

Aug 11, 26After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’biospace

Aug 11, 26After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’fiercebiotech

Jul 30, 26Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storebiospace

Jul 22, 26Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growthbiospace

Jul 16, 26Chutes & Ladders—Cue lines up new CMO and research headfiercebiotech

← prevpage 1 of 2next →